Craft
  • Home
  •  / Adamas Pharmaceuticals
Adamas Pharmaceuticals

Adamas Pharmaceuticals

Revenue

$74.5 M

FY, 2020

Market Capitalization

$371.2 M

2021-11-12

Adamas Pharmaceuticals Summary

Company summary

Overview
Adamas Pharmaceuticals discovers and develops therapies to improve the daily lives of people affected by chronic neurologic disorders. The Company pioneered a platform to develop medicines for chronic neurologic disorders, which is built upon its understanding of time-dependent biologic processes responsible for specific disease activities and drug response.Adamas Pharmaceuticals' lead product candidate, ADS-5102, is a high-dose amantadine therapy in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. It is also investigating ADS-4101, modified-release lacosamide capsules, for the treatment of partial-onset seizures in patients with epilepsy.Additionally, Adamas' licensed assets for the treatment of moderate to severe Alzheimer’s disease, Namenda XR® extended-release capsules, and Namzaric® capsules, are currently marketed by Allergan.
Type
Public
Founded
2002
HQ
Emeryville, CA, US | view all locations
Website
http://www.adamaspharma.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Neil F. McFarlane

    Neil F. McFarlane, Chief Executive Officer

    • Alf Merriweather
    • Christopher B. Prentiss

      Christopher B. Prentiss, Chief Financial Officer

      • Rajiv Patni

        Rajiv Patni, Chief Medical Officer / R&D Head

      LocationsView all

      1 location detected

      • Emeryville, CA HQ

        United States

        1900 Powell St #750

      Adamas Pharmaceuticals Financials

      Summary financials

      Revenue (Q3, 2021)
      $24.6M
      Cash (Q3, 2021)
      $78.6M

      Footer menu